Radotinib dihydrochloride

• CAT Number: I000640
• CAS Number: 926037-85-6
• PubChem Substance ID: 131863586
• Molecular Formula: C27H23Cl2F3N8O
• Molecular Weight: 603.431
• Purity: ≥95%
• IUPAC Name: 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyrazin-2-ylpyrimidin-2-yl)amino]benzamide;dihydrochloride
• InChI: InChI=1S/C27H21F3N8O.2ClH/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38;;/h3-15H,1-2H3,(H,35,39)(H,33,36,37);2*1H
• InChIKey: GEWCZTBAWRSKBX-UHFFFAOYSA-N
• SMILES: CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=NC=CN=C5.Cl.Cl

Radotinib dihydrochloride (CAT: I000640) is a small molecule drug that acts as a potent and selective inhibitor of BCR-ABL tyrosine kinase, a protein that plays a key role in the development of chronic myeloid leukemia (CML). By inhibiting BCR-ABL tyrosine kinase, radotinib can block the proliferation and survival of cancer cells, inducing their death. It has been approved for the treatment of adult patients with CML who have previously received at least one tyrosine kinase inhibitor (TKI) or are intolerant to TKIs. Radotinib dihydrochloride is also being studied for the treatment of other cancers and has shown promising results in preclinical studies.